Lilly to build $6.5 billion Houston plant for orforglipron and other pills

Eli Lilly said on Sept. 23, 2025 that it plans to build a $6.5 billion manufacturing plant in Houston to make active pharmaceutical ingredients, including ingredients for orforglipron, the company's experimental once-daily GLP-1 pill ^[1][5][6].

The site, at the Generation Park development in the Lake Houston area northeast of the city, would total about 1 million square feet in Harris County ^[2]. It is the second of four new U.S. plants Lilly has said it will announce this year, and the eighth U.S. manufacturing facility the company has announced since 2020 ^[1]. Lilly expects it to be operational within five years ^[1].

The company said the plant will bring 615 permanent jobs to the Houston area — engineers, scientists, operations personnel and lab technicians — and generate about 4,000 construction jobs while it is built ^[1]. Texas extended a $5.5 million grant from the Texas Enterprise Fund, and the project was approved under the state's Jobs, Energy, Technology and Innovation program ^[2]. Lilly chose Generation Park from more than 300 applications, citing workforce potential, local incentives, utilities, transportation and business climate ^[1].

What the plant will make

The Houston site is designed to produce small molecule medicines across several areas, including cardiometabolic health, oncology, immunology and neuroscience ^[1]. Reuters reported that the facility will make active pharmaceutical ingredients for orforglipron and for some of Lilly's cancer, autoimmune and other advanced therapies ^[6].

Lilly CEO David Ricks told Reuters the Houston plant would be a major hub for orforglipron production, while the drug will also be made at a site in Indiana, and that Houston would make orforglipron primarily plus some precursor materials ^[6]. Ricks said Texas was chosen partly for the area's chemical engineering expertise, skilled labor and construction support ^[6].

Orforglipron is a daily pill and a small molecule GLP-1 receptor agonist. Lilly expects to submit it to global regulatory agencies for obesity by the end of this year ^[1]. It is not approved. Data from a late-stage study showed the pill helped patients lose 12.4% of their body weight ^[6], and Jefferies analyst Akash Tewari estimated in a note that it could generate around $25 billion in annual peak sales ^[6]. Analysts have said the drug is a candidate for a one- to two-month fast-track review process recently launched by the U.S. Food and Drug Administration ^[6].

"Our new Houston site will enhance Lilly's ability to manufacture orforglipron at scale and, if approved, help fulfill the medicine's potential as a metabolic health treatment for tens of millions of people worldwide who prefer the ease of a pill that can be taken without food and water restrictions," Ricks said in the company's announcement ^[1].

The Houston project is part of a larger buildout. Lilly pledged at least $27 billion in February for four new U.S. plants, which adds to $23 billion in earlier investments since 2020 ^[5]. Houston Public Media described the new sites as part of $50 billion in domestic projects since 2020 ^[7]. Lilly announced a $5 billion site in Goochland County, Virginia, the week before the Houston news ^[6]. The company has said it will announce the two remaining locations this year ^[1].

Why it matters for patients

Lilly and rival Novo Nordisk have previously run into supply constraints on their weekly GLP-1 injections as demand rose in the U.S., and adding capacity has been part of both companies' response ^[5]. The Houston plant is meant to add domestic capacity for a future pill version of the drug class, but it will not change what is available now: orforglipron has not been approved, and Lilly expects to file for approval for obesity by the end of this year ^[1].

The plant itself is not expected to be making medicines for up to five years ^[1], so it would not affect supplies of currently marketed GLP-1 drugs in the near term. Nothing in the announcement says how orforglipron would be priced or whether insurers would cover it; those details have not been disclosed. The broader U.S. manufacturing push is also happening as President Donald Trump has threatened tariffs on pharmaceuticals imported into the country ^[5][6].

What happens next

Lilly plans to submit orforglipron to global regulators for obesity by the end of 2025 ^[1]. It also plans to name the two remaining U.S. plant locations this year ^[1]. The company expects all four new sites to begin making medicines within five years ^[5], and the Houston facility to be operational within five years of the September 2025 announcement ^[1].